Theresa Winhusen, PhD [email]
Principal Investigator
University of Cincinnati
Addiction Sciences Division
3131 Harvey Ave.
Cincinnati, OH 45219

Find Node Publications
Node Facebook page
Node Twitter feed
Node newsletter
NIDA web site

The Ohio Valley Node joined the Clinical Trials Network in September 2000. As of September 2010, the OVN consists of 23 community-based treatment programs in 15 states in the Midwest region of the United States: West Virginia, Ohio, Kentucky, Tennessee, Michigan, Wisconsin, Illinois, Indiana, Missouri, Minnesota, Kansas, South Dakota, North Dakota, Iowa, and Nebraska. The community-based treatment programs include specialty addiction treatment centers representing differently modalities of care; as well as general medical settings of care such as emergency rooms, HIV clinics and family practice centers.  The OVN has participated in over 25 national multi-site clinical trial studies and is one of the most productive CTN nodes in the country.


CTN-0001 Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
CTN-0002 Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
CTN-0008 Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation
CTN-0012 Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
CTN-0013 Motivational Enhancement Therapy to Improve Treatment Utilization and Outcome in Pregnant Substance Users
CTN-0014 Brief Strategic Family Therapy for Adolescent Drug Abusers
CTN-0014-A-1 Mediators and Moderators of Brief Strategic Family Therapy (BSFT) for Adolescent Drug Use
CTN-0015 Women's Treatment for Trauma and Substance Use Disorders
CTN-0018 Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
CTN-0019 Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment
CTN-0028 Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents (with Substance Use Disorder)
CTN-0029 Attention Deficit Hyperactivity Disorder (ADHD) in Adult Smokers

Prescription Opioid Addiction Treatment Study (POATS)

CTN-0030-A-1 Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
CTN-0031 Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement
CTN-0031-A-1 An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers
CTN-0032 HIV Rapid Testing and Counseling
CTN-0032-A-1 Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs
CTN-0033-Ot-4 An Exploration of Methamphetamine and Other Drug Use and Treatment Options Among Urban and Rural Northern Plains American Indians
CTN-0037 Stimulant Reduction Intervention Using Dosed Exercise (STRIDE)
CTN-0037-A-1 Site Influences on Treatment Effects - Exercise as a Treatment for Substance Use Disorders
CTN-0042-S Efficacy of Motivational Enhancement Therapy for African Americans
CTN-0044 Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
CTN-0044-A-2 Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
CTN-0046 Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant Dependence
CTN-0047 Screening Motivational Assessment and Referral to Treatment in Emergency Departments (SMART-ED): Evaluation of Screening, Brief Intervention, Referral to Treatment (SBIRT) and Booster Session for Drug Use Patients Presenting for Treatment in the Emergency Department
CTN-0048 Cocaine Use Reduction with Buprenorphine (CURB)
CTN-0049 Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users (Project HOPE)
CTN-0051 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
CTN-0051-A-1 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study
CTN-0051-A-2 Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051
CTN-0052 Buspirone for Relapse Prevention in Adults with Cocaine Dependence (BRAC)
CTN-0053 Achieving Cannabis Cessation -- Evaluating N-Acetylcystein Treatment (ACCENT)
CTN-0055 Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES)
CTN-0064 Linkage to Hepatitis C Virus (HCV) Care among HIV/HCV Co-infected Substance Users

Medication Treatment for OPioid Use Disorder in Expectant Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations


Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 8/2017 -- http://ctndisseminationlibrary.org/nodes/ovnode.htm